On Thursday, Shares of Planet Fitness, Inc. (NYSE:PLNT), remained unchanged to $16.
Planet Fitness declared the pricing of its initial public offering of 13,500,000 shares of its Class A common stock at a public offering price of $16.00 per share. In addition, the Company and certain selling stockholders have granted the underwriters a 30-day option to purchase up to an additional 2,025,000 shares of the Company’s Class A common stock at the initial public offering price, less underwriting discounts and commissions.
The closing for the offering is predictable to occur on August 11, 2015, subject to the satisfaction of customary closing conditions.
J.P. Morgan, BofA Merrill Lynch, Jefferies and Credit Suisse are acting as active book-running managers of the projected offering. Guggenheim Securities, Robert W. Baird, William Blair and Piper Jaffray are acting as junior book-running managers. Cowen & Company is acting as a co-manager.
Founded in 1992 in Dover, N.H., Planet Fitness is one of the largest and fastest-growing franchisors and operators of fitness centers in the United States by number of members and locations.
Shares of Aimmune Therapeutics, Inc. (NASDAQ:AIMT), skyrocketed 50.63% to $24.10, during its last trading session, hitting its highest level.
Aimmune Therapeutics declared the pricing of its initial public offering of 10,000,000 shares of its common stock at a public offering price of $16.00 per share, before underwriting discounts and commissions. In addition, Aimmune has granted the underwriters a 30-day option to purchase up to an additional 1,499,999 shares of common stock at the same price.
The offering is predictable to close on August 11, 2015, subject to satisfaction of customary closing conditions.
BofA Merrill Lynch, Credit Suisse and Piper Jaffray are acting as joint book-running managers for the offering.
Aimmune Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the development of desensitization treatments for peanut and other food allergies. Its characterized oral desensitization immunotherapy comprises AR101, a product for the treatment of peanut allergy in children and adults that has accomplished a Phase II study.
Finally, TerraForm Power, Inc. (NASDAQ:TERP), ended its last trade with -11% loss, and closed at $25.97.
TerraForm Power stated second quarter 2015 financial results, counting CAFD of $65 million for the quarter.
Q2 Financial Results
TerraForm Power stated adjusted revenue of $132 million, Adjusted EBITDA of $108 million, and CAFD of $65 million in the second quarter. Revenue and Adjusted EBITDA reflect recognition of partial economic ownership during the period for the acquisitions of the Integrys, Duke, Invenergy Solar, and Moose Power portfolios, which were accomplished during Q2. Pro forma for a full quarter of economic ownership, revenue and Adjusted EBITDA would have been $139 million and $114 million, respectively.
Q2 Dividend Enhance
TerraForm Power declared that its Board of Directors has declared a second quarter dividend for TerraForm Power’s Class A common stock of $0.335 per share, or $1.34 per share on an annualized basis. This represents a 3% enhance from the first quarter 2015 dividend of $0.325 per share, or $1.30 per share on an annualized basis. Additionally, this represents a 48% enhance from TerraForm Power’s initial IPO dividend one year ago. The Q2 dividend is payable on September 15, 2015 to shareholders of record as of September 1, 2015.
TerraForm Power, Inc. owns and operates solar and wind generation assets serving utility, commercial, and residential customers. As of February 20, 2015, its portfolio comprised of solar and wind projects located in the United States, Canada, the United Kingdom, and Chile with an aggregate nameplate capacity of 1,507.3 megawatt.
DISCLAIMER:
This article is published by www.wsnewspublishers.com. The Content included in this article is just for informational purposes only. All information used in this article is believed to be from reliable sources, but we make no representations or warranties of any kind, express or implied, about the completeness, accuracy, or reliability with respect to this article.
All visitors are advised to conduct their own independent research into individual stocks before making a purchase decision.
Information contained in this article contains forward-looking information within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, counting statements regarding the predictable continual growth of the market for the corporation’s products, the corporation’s ability to fund its capital requirement in the near term and in the long term; pricing pressures; etc.
Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, aims, assumptions, or future events or performance may be forward looking statements. Forward-looking statements are based on expectations, estimates, and projections at the time the statements are made that involve a number of risks and uncertainties, which could cause actual results or events to differ materially from those presently anticipated. Forward looking statements may be identified with such words as expects, will, anticipates, estimates, believes, or by statements indicating certain actions may, could, should/might occur.
